Scientists discover potential way to treat and prevent cancer in children (neuroblastoma)

(Children's Cancer Institute Australia) The MYCN oncogene is known to be a key cause of a number of deadly solid tumour cancers, including neuroblastoma which claims more lives of children under 5 than any other cancer. In new research, a team led by Professor Michelle Haber AM, Executive Director, and Professor Murray Norris AM, Deputy Director, Children's Cancer Institute, Australia, has uncovered a previously unknown crucial link between polyamines and MYCN, offering a new way to target childhood cancers.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

GPAID was designed to treat high ‐risk neuroblastoma, including relapsed or refractory disease. GPAID targets neuroblastoma cells in the same way as MIBG. It also cotargets DNA of proliferating cells, an attribute especially advantageous in the treatment ofMYCN‐amplified tumors. Neuroblastoma, the most common extracranial solid tumor in children, accounts for nearly 8% of childhood cancers in the United States. It is a disease with pronounced clinical and biological heterogeneities. The amplification ofMYCN, whose key tumorigenic functions include the promotion of proliferation, facilitation of the cell's entry into th...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
Neuroblastoma, the most common extracranial solid tumor in children, accounts for nearly 8% of childhood cancers in the United States. It is a disease with pronounced clinical and biological heterogeneities. The amplification ofMYCN, whose key tumorigenic functions include the promotion of proliferation, facilitation of the cell's entry into the S phase and prevention of cells from leaving the cell cycle, correlates with poor prognosis. Patients with a high proliferation index disease have low survival rates. Neuroblastoma is one of the most radioresponsive of all human tumors. To exploit this radiosensitivity, radioactive...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors associated with high cardiovascular morbidity and variable risk of malignancy. The current therapy of choice is surgical resection. Nevertheless, PCCs/PGLs are associated with a lifelong risk of tumor persistence or recurrence. A high rate of germline or somatic mutations in numerous genes has been found in these tumors. For some, the tumorigenic processes are initiated during embryogenesis. Such tumors carry gene mutations leading to pseudohypoxic phenotypes and show more immature characteristics than other chromaffin cell tumors; they are also ...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
ierkens Neuroblastoma (NBL) is the most common extracranial solid tumor in childhood. Despite intense treatment, children with this high-risk disease have a poor prognosis. Immunotherapy showed a significant improvement in event-free survival in high-risk NBL patients receiving chimeric anti-GD2 in combination with cytokines and isotretinoin after myeloablative consolidation therapy. However, response to immunotherapy varies widely, and often therapy is stopped due to severe toxicities. Objective markers that help to predict which patients will respond or develop toxicity to a certain treatment are lacking. Immunothera...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: April 2020Source: Cancer Epidemiology, Volume 65Author(s): Julie Volk, Julia E. Heck, Kjeld Schmiegelow, Johnni HansenAbstractBackgroundParental occupational exposures are suggested as contributing causes of childhood cancer.MethodsChildren age
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Childhood cancer survivors (CCSs) from high-grade malignancies, such as high-risk neuroblastoma, have been increased, and second malignant neoplasm, becomes a serious problem for CCSs. However, detailed reports about rare types of second cancer such as gastric cancer remain limited. We herein reported a female patient who developed diffuse type gastric carcinoma after 21 years from completion of treatment to high-risk neuroblastoma. We reviewed the previous cohort studies for second gastrointestinal cancer in CCSs and the case reports with second gastric carcinoma for CCSs. We presumed second gastric cancer was refractory ...
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Clinical and Laboratory Observations Source Type: research
Neuroblastoma is the most common extracranial solid tumor of childhood. The high rate of recurrence is associated with a low survival rate for patients with high-risk neuroblastoma. There is thus an urgent nee...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
(Uppsala University) Using a computer algorithm, scientists at Uppsala University have identified a promising new treatment for neuroblastoma. This form of cancer in children, which occurs in specialised nerve cells in the sympathetic nervous system, may be life-threatening. In the long term the discovery, described in the latest issue of the scientific journal Nature Communications, may result in a new form of treatment for children in whom the disease is severe or at an advanced stage.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Neuroblastoma (NB) is one of most common childhood tumors with high mortality among children worldwide. microRNAs (miRNAs) have been reported to play essential roles in the pathogenesis and therapeutics of NB....
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Neuroblastoma (NB) predominantly presents as high-risk disease, requiring intensive multimodal therapy. Proton beam therpy (PBT) is a promising option for many childhood cancers, but is not widely available. Patients with NB hoping to receive PBT may therefore need to be transferred between institutions during intensive multimodal therapy, risking undesirable effects. We evaluated patients with high-risk NB who received PBT at our institute as part of first-line therapy, mainly focusing on the safety and feasibility of mid-treatment patient transfer. Eighteen patients with newly diagnosed high-risk NB who received PBT betw...
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
More News: Australia Health | Brain | Cancer | Cancer & Oncology | Childhood Cancer | Children | International Medicine & Public Health | Neuroblastoma | Neurology